查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1827433

性與生殖健康藥物市場（依藥物類別、作用機制、處方狀態、給藥途徑、通路和最終用戶分類）－2025-2032 年全球預測

Sexual & Reproductive Health Drugs Market by Drug Class, Mechanism Of Action, Prescription Status, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年性與生殖藥物市場將成長至 1,002.6 億美元，複合年成長率為 13.72%。

主要市場統計數據
基準年2024年 358.3億美元
預計2025年 407.2億美元
預測年份：2032年 1002.6億美元
複合年成長率（%） 13.72%

對塑造性與生殖醫學的當代促進因素、臨床創新和不斷變化的患者期​​望的權威介紹。

性與生殖健康治療領域正處於臨床創新、不斷發展的監管格局和不斷變化的患者期​​望的交匯點。避孕技術的進步、愛滋病毒預防策略的擴展、生育治療和荷爾蒙替代通訊協定正與數位醫療解決方案和不斷發展的報銷模式相融合，這使得策略清晰度變得愈發緊迫。為此，從製造商相關人員付款人再到醫療系統的利害關係人正在重新評估產品系列、經銷夥伴和證據生成的優先事項，以符合以患者為中心的醫療路徑。

同時，人口結構的變化和性行為模式的改變正在重塑不同族群的需求模式。年輕族群對使用者控制和謹慎的給藥系統越來越感興趣，而老年族群對荷爾蒙療法和生育療法的需求也日益成長。因此，對製劑多樣性、依從性支援技術和安全監測的投資正成為維持臨床相關性和競爭差異化的關鍵。本介紹將深入探討變革性轉變、貿易政策的影響、細分市場的細微差別、區域動態、企業策略，並為引領下一階段市場發展的領導者提供實用建議。

技術創新、監管演變和病患行為變化如何共同重塑產品開發、取得和商業策略

性與生殖健康治療領域正經歷多重同步變革時期，這些變革正在重新定義產品價值和相關人員的參與。從植入式避孕藥、長效注射劑到經皮系統，藥物傳遞技術創新日益強調耐用性、便利性和依從性。同時，數位健康平台和遠端醫療的發展使得遠端處方、虛擬諮詢和依從性監測成為可能，從而降低了傳統的獲取障礙，並催生了新的分銷模式。

監管趨勢也在發生變化，為了因應尚未滿足的臨床需求，自適應路徑和加速審查機制正變得越來越普遍。這種監管靈活性鼓勵在生命週期的早期階段進行投資，並促進開發商和監管機構之間更密切的對話。此外，將真實世界證據和病患報告結果納入監管文件，也提升了上市後監測和持續品質改進的重要性。在商業性，基於價值的合約和結果掛鉤定價正變得越來越普遍，這鼓勵製造商將臨床終點與付款人的期望和以患者為中心的指標相結合。

最後，社會和人口因素，例如避孕自主權的增強、愛滋病預防意識的提升以及生育治療的規範化，正在重塑需求結構。因此，能夠透過靈活的分銷策略和強力的循證項目來打造臨床差異化的公司將在這個不斷發展的市場中佔據最佳地位，獲得長期的競爭力。

評估 2025 年美國關稅實施對更廣泛的供應鏈、採購和臨床連續性的影響

2025年美國關稅的實施對性與生殖健康治療的供應鏈、籌資策略和定價結構產生了即時且連鎖的影響。依賴跨國採購活性藥物成分、包裝組件和給藥裝置的製造商不得不重新考慮籌資策略，以減輕利潤壓力。因此，為了保護生產免受關稅波動的影響並保持患者護理的連續性，一些公司加快了供應商多元化，並實現了製造地的區域化。

貿易措施也影響了經銷商和付款方層面的採購決策，促使企業重新評估競標計畫和合約條款，以反映日益增加的投入成本不確定性。在某些情況下，下游相關人員推遲了非必要產品線的發布，或優先考慮國內供應鏈的產品，以避免轉嫁關稅。從臨床營運的角度來看，關稅促使企業對庫存緩衝和緊急分銷路線進行更深入的情境規劃，特別是對於需要低溫運輸和特殊處理的注射療法和特殊避孕藥。

同時，關稅加速了在岸產能投資和官民合作關係的策略討論，以確保製造業的韌性。政策制定者採取的應對措施是與產業合作，確定需要加快授權和減免關稅的關鍵藥品和零件，製造商也加強了與供應商的雙邊談判，以管理前置作業時間和不斷上漲的成本。整體而言，2025年的關稅環境凸顯了供應鏈透明度、靈活採購以及與採購利害關係人積極互動的策略要務，以維護病患可及性和商業性穩定性。

深度細分智慧，將藥物類別、給藥途徑和管道的差異與臨床、監管和商業優先事項相結合

理解細分的細微差別對於按藥物類別、機制和獲取途徑處理治療和商業的複雜性至關重要。避孕藥包括植入式避孕藥、注射式避孕藥、子宮內避孕系統、口服避孕藥和經皮吸收貼片。即使是口服避孕藥，各種劑型——膠囊、粉末和片劑——也決定了遵從性和製造選擇。生育藥物分為 GnRH 類似物、促性腺激素分泌和促排卵劑，每種都有獨特的臨床劑量和監測要求。愛滋病毒預防抗逆轉錄病毒藥物，特別是含有恩曲他濱和替諾福韋的方案，涉及與公共衛生計劃相交叉的持續預防策略。荷爾蒙療法分為雌激素和黃體素途徑，可用於替代和避孕。

激素和非激素藥物作用機制的分類為安全性、副作用概況和患者諮詢提供資訊，進而影響處方模式和安排。處方環境（非處方藥與處方箋藥）決定了照護現場互動、消費者教育需求和自有品牌機會。考慮給藥途徑（注射劑、口服、外用和經皮）進一步透過膠囊、粉末和片劑區分口服製劑，確定低溫運輸要求、依從性考量和設備相容性。分銷管道分為醫院藥房、網路藥房和零售藥房。零售進一步分為連鎖店和獨立商店，突顯了利潤結構、促銷策略和夥伴關係模式的差異。最後，最終用戶細分，包括診所、居家醫療和醫院，突顯了採購規則、治療通訊協定和報銷途徑的差異，醫院分為私立和公立。結合這些細分，相關人員可以優先考慮臨床開發、最佳化管道策略並設計符合付款人期望和患者偏好的證據生成。

區域比較突顯了全球主要市場的監管複雜性、分銷實踐和患者行為模式

美洲、歐洲、中東和非洲以及亞太地區的區域動態差異顯著，監管環境、病患行為和分銷基礎設施各不相同，這些都對策略產生重大影響。在美洲，整合照護模式的普及率高，且私人支付市場成熟，這支持了差異化醫療服務的快速擴張，而公共衛生計畫則推動了愛滋病預防、抗逆轉錄抗逆轉錄病毒和計劃生育計畫的舉措。跨境關係和多樣化的支付方組合使得靈活的定價和上市計劃成為必要。

歐洲、中東和非洲的監管協調工作錯綜複雜，採購能力也千差萬別。在許多市場，集中的報銷決策和強大的公共部門採購管道有利於擁有強健衛生經濟證據的療法。在亞太地區，已開發國家正在加速採用數位化依從性工具和長效療法，而其他市場則優先考慮在地化生產、價格可負擔性以及透過零售和醫院網路進行可擴展分銷。在所有地區，符合文化背景的患者參與和細緻的監管指導仍然是成功進入市場並持續應用的先決條件。

深入了解領先的開發商如何協調產品組合創新、製造夥伴關係和證據策略，以確保臨床和商業性優勢

生殖治療領域的企業策略日益受到產品組合廣度、實證敏捷性和夥伴關係關係成熟度的影響。領先的研發機構正在平衡對長效給藥平台（例如植入和注射劑）的投資，以及對下一代口服和經皮製劑的投資，以滿足不同患者的偏好。為了支持這些創新，各公司正在改進臨床試驗設計，使其具有可操作的終點，並納入患者報告的結果指標，以促進報銷討論並展示現實世界的價值。

與受託製造廠商和專業設備製造商建立策略聯盟正變得越來越普遍，以降低風險並加快複雜製劑的上市時間。在商業性，企業正在多元化其分銷策略，包括直接銷售管道、與線上藥局的合作以及針對診所網路的客製化計畫。此外，企業正在投資上市後監測基礎設施和藥物安全檢測能力，以保持信譽並滿足不斷變化的監管要求。那些兼具製造韌性、主導商業化和敏捷夥伴關係模式的企業將最有可能獲得長期的臨床和商業性相關性。

為高階主管提供切實可行的建議，以加強供應鏈、證據產生和全通路分銷，加速採用並保持訪問

產業領導者應採取整合方法，將臨床創新與彈性供應鏈和以客戶為中心的分銷策略相結合。優先考慮採購多元化和擴大區域生產能力，以降低關稅和地緣政治風險，同時投資於品管系統和供應商關係，以維護產品完整性。在考慮供應的同時，加快證據生成項目，將真實世界結果和患者報告的指標納入其中，以支持報銷談判，並在不同的付款方環境中展示價值。

從商業性角度來看，我們將開發一種全通路分銷模式，將診所處方與線上藥局管道以及有針對性的零售夥伴關係關係相結合，以擴大非處方藥的可及性，同時確保對處方箋依賴性治療進行適當的臨床監管。我們還將部署用於依從性支援、遠端諮詢和藥物安全檢測的數位化工具，以改善患者療效並收集有意義的上市後數據。最後，我們將與公共衛生項目和付款方建立合作關係，使產品引入與人口健康優先事項保持一致，提高可及性，並為更廣泛的應用創造可擴展的途徑。此類合作行動將增強市場韌性，並加速臨床差異化治療方法的採用。

結合主要相關人員訪談、監管機構分析和資料三角測量的嚴格混合方法研究框架產生了可行的見解

支撐本分析的調查方法結合了初步定性訪談、監管指南的系統性回顧以及專有臨床和商業資料集的三角檢驗，以確保獲得可靠、多觀點的洞察。初步研究包括對臨床醫生、供應鏈經理、付款人和藥屋主任的結構化訪談，以了解實踐現狀和不斷變化的偏好。這些洞察與對監管趨勢、核准途徑和上市後監管要求的全面回顧相結合，以評估政策變化如何與臨床實踐相互作用。

數據三角檢驗交叉引用了官方監管備案文件、臨床試驗註冊中心和配銷通路資訊，以檢驗專題研究結果。此方法優先考慮假設的透明度和對資訊來源的嚴格記錄。在相關情況下，我們進行了情境規劃練習，以探索供應鏈中斷或政策轉變對營運的影響，並進行了敏感度分析，以檢驗策略建議在不同市場條件下的穩健性。此混合方法框架支持基於一線經驗以及已記錄的監管和臨床科學得出可行的結論。

策略結論強調，需要證據完整性、供應鏈彈性和以病人為中心的商業化來維持成長

總而言之，性與生殖醫學領域的特點是技術快速進步、監管格局不斷演變以及患者需求不斷變化，這些因素共同創造了機遇，也帶來了複雜性。長效給藥系統、口服和經皮製劑的多樣化以及對數位化依從性工具的日益依賴，正在重新定義治療的價值提案。同時，由於貿易動態和監管的地區差異，需要建立有韌性的供應鏈和靈活應變的市場進入策略，以保障病患用藥和商業性可行性。

相關人員若能投資於符合付款人需求的證據生成，建構靈活的生產和分銷網路，並部署以病人為中心的商業模式，將最有可能保持成長並產生臨床影響。隨著市場格局的不斷發展，與臨床、監管和供應鏈合作夥伴的持續合作對於將創新轉化為有意義的患者治療效果並管理營運風險至關重要。本文提供的見解將為企業在這一重要治療領域應對短期挑戰並掌握長期機會奠定策略基礎。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 透過遠端醫療管道快速採用自行注射皮下避孕藥
  • 非專利levonorgestrel子宮內避孕器競爭對手的擴張導致已開發市場價格下跌
  • 非荷爾蒙口服男性避孕藥後期臨床試驗的臨床進展
  • 多個地區放寬了非處方事後緊急避孕藥的限制
  • 透過整合數位妊娠追蹤應用程式和處方荷爾蒙療法實現個人化劑量
  • 生物相似濾泡刺激素產品的激增正在改變不孕症治療的成本動態
  • 注射型 PrEP 產品的需求增加，此產品可提供每月預防 HIV 感染的保護
  • 針對復發性細菌性陰道炎的新興微生物組標靶陰道療法
  • 政策主導利用米非司酮郵購網路擴大遠端醫療墮胎服務

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 性與生殖健康藥物市場（依藥物類別）

  • 避孕藥
    • 植入式避孕器
    • 注射避孕藥
    • 子宮內避孕系統
    • 口服避孕藥
      • 膠囊
      • 粉末
      • 藥片
    • 經皮吸收貼片
  • 治療勃起功能障礙
  • 生育藥物
    • GnRH類似物
    • 促性腺激素分泌
    • 促排卵藥物
  • HIV預防抗逆轉錄病毒物
    • 恩曲他濱
    • 替諾福韋
  • 荷爾蒙療法
    • 雌激素治療
    • 黃體素治療

9. 性與生殖藥物市場（依作用機制）

  • 荷爾蒙
  • 非荷爾蒙

第 10 章。依處方情況分類的性與生殖保健藥物市場

  • OTC
  • 處方

11. 性與生殖藥物市場（依給藥途徑）

  • 注射
  • 口服
    • 膠囊
    • 粉末
    • 藥片
  • 外用
  • 經皮

第 12 章。 性與生殖保健藥物市場（按分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局
    • 連鎖藥局
    • 獨立藥房

13. 性與生殖藥物市場（依最終用戶）

  • 診所
  • 居家照護
  • 醫院
    • 私立醫院
    • 公立醫院

14. 性與生殖保健藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 15 章。性與生殖藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 性與生殖保健藥物市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Bayer AG
    • Pfizer Inc.
    • Merck & Co., Inc.
    • AbbVie Inc.
    • Ferring BV
    • Teva Pharmaceutical Industries Limited
    • Organon & Co.
    • Gedeon Richter Plc
    • HRA Pharma SAS
    • Eli Lilly and Company
Product Code: MRR-434CCDA0523A

The Sexual & Reproductive Health Drugs Market is projected to grow by USD 100.26 billion at a CAGR of 13.72% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 35.83 billion
Estimated Year [2025] USD 40.72 billion
Forecast Year [2032] USD 100.26 billion
CAGR (%) 13.72%

An authoritative introduction to contemporary drivers, clinical innovations, and evolving patient expectations shaping sexual and reproductive health therapeutics

The sexual and reproductive health therapeutics landscape sits at a crossroads of clinical innovation, regulatory evolution, and shifting patient expectations. Advances in contraceptive technologies, extended HIV prevention strategies, fertility interventions, and hormone replacement protocols are converging with digital health solutions and evolving reimbursement models to create renewed urgency for strategic clarity. In response, stakeholders from manufacturers to payers and health systems are re-evaluating product portfolios, distribution partnerships, and evidence generation priorities to align with patient-centered care pathways.

At the same time, demographic shifts and changing patterns of sexual behavior are reshaping demand profiles across population segments. Younger cohorts demonstrate rising interest in user-controlled methods and discreet delivery systems, while aging populations heighten demand for hormonal therapies and fertility care. Consequently, investment in formulation diversity, adherence-support technologies, and safety monitoring is becoming central to maintaining clinical relevance and competitive differentiation. This introduction sets the stage for a deeper examination of transformative shifts, trade policy impacts, segmentation nuance, regional dynamics, company strategies, and pragmatic recommendations for leaders navigating the next phase of market evolution.

How technological innovation, regulatory evolution, and shifting patient behaviors are converging to reshape product development, access, and commercial strategies

The landscape for sexual and reproductive health therapeutics is undergoing multiple, simultaneous transformations that are redefining product value and stakeholder engagement. Technological innovations in drug delivery-ranging from implantable contraceptives and long-acting injectables to transdermal systems-are increasing the emphasis on durability, convenience, and adherence. Meanwhile, the growth of digital health platforms and telemedicine is enabling remote prescribing, virtual counseling, and adherence monitoring, thereby reducing traditional access barriers and enabling new distribution models.

Regulatory trajectories are also shifting, with adaptive pathways and accelerated review mechanisms becoming more prevalent in response to unmet clinical needs. This regulatory agility is encouraging earlier lifecycle investments and closer dialogue between developers and authorities. Additionally, the integration of real-world evidence and patient-reported outcomes into regulatory dossiers is elevating the importance of post-market surveillance and continuous quality improvement. Commercially, value-based contracting and outcomes-linked pricing are gaining traction, prompting manufacturers to align clinical endpoints with payer expectations and patient-centered measures.

Finally, social and demographic forces-such as increasing contraceptive autonomy, expanded HIV prevention awareness, and the normalization of fertility interventions-are reshaping demand composition. As a result, organizations that can combine clinical differentiation with flexible distribution strategies and robust evidence programs will be best positioned to capture long-term relevance in this evolving market.

Assessing the wide-ranging supply chain, procurement, and clinical continuity effects stemming from the United States tariffs introduced in 2025

The introduction of United States tariffs in 2025 has created immediate and cascading effects across supply chains, procurement strategies, and pricing architecture for sexual and reproductive health therapeutics. Manufacturers that rely on cross-border inputs for active pharmaceutical ingredients, packaging components, and delivery devices have had to reassess sourcing strategies to mitigate margin pressure. Consequently, several firms accelerated supplier diversification and regionalized manufacturing footprints to insulate production against tariff volatility and to maintain continuity of care for patients.

Trade measures also influenced procurement decisions at the distributor and payer levels, prompting a re-evaluation of tender timelines and contractual terms to reflect increased input cost uncertainty. In certain cases, downstream stakeholders deferred non-essential pipeline launches or prioritized products with domestic supply chains to avoid exposure to tariff pass-through. From a clinical operations perspective, the tariffs have prompted more intensive scenario planning for inventory buffers and contingency distribution routes, particularly for injectable therapies and specialty contraceptives that require cold chain or specific handling.

In parallel, the tariffs accelerated strategic conversations about onshore capacity investment and public-private partnerships to secure manufacturing resilience. Policymakers responded by engaging with industry to identify critical medicines and components warranting expedited permitting or tariff relief, while manufacturers intensified bilateral negotiations with suppliers to manage lead times and cost escalation. Overall, the tariff environment in 2025 underscored the strategic imperative of supply chain transparency, flexible sourcing, and active engagement with procurement stakeholders to preserve patient access and commercial stability.

Deep segmentation intelligence that aligns drug class nuances, administration routes, and channel distinctions to clinical, regulatory, and commercial priorities

A nuanced understanding of segmentation is essential to navigate the therapeutic and commercial complexity across drug classes, mechanisms, and access pathways. Examining drug class distinctions reveals divergent development and commercialization dynamics: contraceptives encompass implantable contraceptives, injectable contraceptives, intrauterine systems, oral contraceptives, and transdermal patches; within oral contraceptives, formulation variation across capsules, powders, and tablets shapes adherence and manufacturing choices. Fertility therapies are distinguished by GnRH analogues, gonadotropins, and ovulation inducers, each with unique clinical administration and monitoring requirements. HIV prevention antiretrovirals, notably regimens including emtricitabine and tenofovir, involve sustained prophylactic strategies that intersect with public health programming, while hormonal therapies split into estrogen and progesterone pathways that serve both replacement and contraceptive indications.

Mechanism of action segmentation between hormonal and non-hormonal agents informs safety, side-effect profiles, and patient counseling, which in turn affects prescribing patterns and formulary placement. Prescription status-differentiating over-the-counter availability from prescription-only products-shapes point-of-care interactions, consumer education needs, and private-label opportunities. Route of administration considerations, spanning injectable, oral, topical, and transdermal modes with oral forms further differentiated by capsules, powders, and tablets, determine cold chain requirements, adherence considerations, and device compatibility. Distribution channel segmentation across hospital pharmacy, online pharmacy, and retail pharmacy, with retail further split into chain and independent outlets, highlights divergent margin structures, promotional strategies, and partnership models. Finally, end user segmentation including clinics, home care, and hospitals, with hospitals categorized as private and public, underscores differing procurement rules, treatment protocols, and reimbursement pathways. Taken together, these segmentation lenses allow stakeholders to prioritize clinical development, optimize channel strategies, and design evidence generation that aligns with both payer expectations and patient preferences.

Comparative regional intelligence highlighting regulatory complexity, distribution realities, and patient behavior patterns across major global markets

Regional dynamics vary markedly across the Americas, Europe, Middle East & Africa, and Asia-Pacific, with each region presenting distinct regulatory landscapes, patient behaviors, and distribution infrastructures that materially influence strategy. In the Americas, high adoption of integrated care models and mature private pay markets support rapid uptake of differentiated delivery systems, while public health programs drive scale for HIV prevention antiretrovirals and family planning initiatives. Cross-border trade relationships and heterogenous payer mixes require adaptable pricing and market access plans.

Europe, Middle East & Africa presents a complex mosaic of regulatory harmonization efforts alongside significant variability in procurement capabilities. In many markets, centralized reimbursement decision-making and strong public sector purchasing channels favor therapies with robust health economic evidence, whereas emerging economies within the region signal demand for cost-effective, easy-to-administer solutions. Asia-Pacific demonstrates a bifurcated picture: advanced economies accelerate adoption of digitally enabled adherence tools and long-acting therapeutics, while other markets prioritize manufacturing localization, affordability, and scalable distribution through retail and hospital networks. Across all regions, culturally informed patient engagement and nuanced regulatory navigation remain prerequisites for successful market entry and sustained uptake.

Insights into how leading developers are aligning portfolio innovation, manufacturing partnerships, and evidence strategies to secure clinical and commercial advantage

Company strategies in the sexual and reproductive health therapeutics space are increasingly defined by portfolio breadth, evidence generation agility, and partnership sophistication. Leading developers are balancing investments in long-acting delivery platforms-such as implants and injectables-with next-generation oral and transdermal formulations to appeal to diverse patient preferences. To support these innovations, firms are strengthening clinical trial design with pragmatic endpoints and incorporating patient-reported outcome measures to facilitate reimbursement discussions and to demonstrate real-world value.

Strategic alliances with contract manufacturing organizations and specialized device manufacturers are becoming more common as companies seek to de-risk complex formulation launches and to accelerate time-to-market. Commercially, firms are diversifying distribution strategies to include direct-to-consumer channels, partnerships with online pharmacies, and tailored programs for clinic networks, thereby expanding reach while preserving professional oversight where clinically required. Additionally, companies are investing in post-market surveillance infrastructure and pharmacovigilance capabilities to sustain trust and comply with evolving regulatory expectations. Those that combine manufacturing resilience, evidence-led commercialization, and nimble partnership models will be best placed to capture long-term clinical and commercial relevance.

Actionable recommendations for executives to fortify supply chains, evidence generation, and omnichannel distribution to accelerate adoption and preserve access

Industry leaders should pursue an integrated approach that aligns clinical innovation with resilient supply chains and customer-centric distribution strategies. Prioritize diversification of sourcing and expansion of regional manufacturing capacity to mitigate tariff and geopolitical risks, while simultaneously investing in quality management systems and supplier relationships to preserve product integrity. Parallel to supply considerations, accelerate evidence-generation programs that incorporate real-world outcomes and patient-reported measures to support reimbursement negotiations and to demonstrate value across diverse payer environments.

From a commercial perspective, develop omnichannel distribution models that blend clinic-based prescribing with online pharmacy access and targeted retail partnerships, ensuring appropriate clinical oversight for prescription-dependent therapies while expanding convenience for over-the-counter options. Embrace digital tools for adherence support, remote counseling, and pharmacovigilance to enhance patient outcomes and to gather meaningful post-launch data. Finally, pursue collaborative engagements with public health programs and payers to align product introductions with population health priorities, thereby enhancing access and creating scalable pathways for broader uptake. These coordinated actions will strengthen market resilience and accelerate adoption of clinically differentiated therapies.

A rigorous mixed-methods research framework combining primary stakeholder interviews, regulatory analysis, and data triangulation to underpin actionable findings

The research methodology underpinning this analysis combined primary qualitative interviews, systematic review of regulatory guidance, and triangulation with proprietary clinical and commercial datasets to ensure robust, multi-perspective insights. Primary research included structured interviews with clinicians, supply chain managers, payers, and pharmacy directors to capture operational realities and evolving preferences. These insights were synthesized with a comprehensive review of regulatory trends, approval pathways, and post-market surveillance requirements to assess how policy shifts interact with clinical practice.

Data triangulation involved cross-referencing public regulatory filings, clinical trial registries, and distribution channel intelligence to validate thematic findings. The approach prioritized transparency in assumptions and rigorous documentation of source provenance. Where relevant, scenario planning exercises were employed to explore the operational implications of supply chain disruptions and policy shifts, and sensitivity analyses were conducted to test the robustness of strategic recommendations under alternative market conditions. This mixed-methods framework supports actionable conclusions that are grounded in both frontline experience and documented regulatory and clinical science.

Strategic conclusions emphasizing the need for evidence alignment, supply chain resilience, and patient-centric commercialization to sustain growth

In conclusion, the sexual and reproductive health therapeutics landscape is characterized by rapid technological progress, evolving regulatory expectations, and shifting patient demand that together create both opportunity and complexity. Long-acting delivery systems, diversified oral and transdermal formulations, and increased reliance on digital adherence tools are redefining therapeutic value propositions. Concurrently, trade dynamics and regional regulatory variation necessitate resilient supply chains and adaptive market access strategies to preserve patient access and commercial viability.

Stakeholders that invest in evidence generation aligned with payer needs, build flexible manufacturing and distribution networks, and deploy patient-centric commercial models will be best positioned to sustain growth and clinical impact. As the landscape continues to evolve, continuous engagement with clinical, regulatory, and supply chain partners will be essential to translate innovation into meaningful patient outcomes while managing operational risk. The insights presented here offer a strategic foundation for organizations seeking to navigate near-term disruptions and to capitalize on long-term opportunities within this critical therapeutic area.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid uptake of self-administered subcutaneous injectable contraceptives via telehealth channels
  • 5.2. Expansion of generic levonorgestrel IUD competitors driving price erosion in developed markets
  • 5.3. Clinical advancement of nonhormonal oral male contraceptives undergoing late stage human trials
  • 5.4. Regulatory loosening of over-the-counter access to emergency contraceptive pills in multiple regions
  • 5.5. Integration of digital fertility tracking apps with prescription hormonal therapies for personalized dosing
  • 5.6. Surge in biosimilar follicle-stimulating hormone products reshaping fertility treatment cost dynamics
  • 5.7. Introduction of mRNA-based therapeutic vaccines targeting HPV-related cervical lesions in clinical research
  • 5.8. Rising demand for injectable PrEP formulations offering monthly protection against HIV infection
  • 5.9. Emergence of microbiome-targeted vaginal therapies for recurrent bacterial vaginosis management
  • 5.10. Policy-driven expansion of telemedicine abortion services with mail-order mifepristone distribution networks

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Sexual & Reproductive Health Drugs Market, by Drug Class

  • 8.1. Contraceptives
    • 8.1.1. Implantable Contraceptives
    • 8.1.2. Injectable Contraceptives
    • 8.1.3. Intrauterine System
    • 8.1.4. Oral Contraceptives
      • 8.1.4.1. Capsules
      • 8.1.4.2. Powders
      • 8.1.4.3. Tablets
    • 8.1.5. Transdermal Patches
  • 8.2. Erectile Dysfunction Treatments
  • 8.3. Fertility Drugs
    • 8.3.1. GnRH Analogues
    • 8.3.2. Gonadotropins
    • 8.3.3. Ovulation Inducers
  • 8.4. HIV Prevention Antiretrovirals
    • 8.4.1. Emtricitabine
    • 8.4.2. Tenofovir
  • 8.5. Hormonal Therapies
    • 8.5.1. Estrogen Therapy
    • 8.5.2. Progesterone Therapy

9. Sexual & Reproductive Health Drugs Market, by Mechanism Of Action

  • 9.1. Hormonal
  • 9.2. Non Hormonal

10. Sexual & Reproductive Health Drugs Market, by Prescription Status

  • 10.1. Over The Counter
  • 10.2. Prescription

11. Sexual & Reproductive Health Drugs Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Oral
    • 11.2.1. Capsules
    • 11.2.2. Powders
    • 11.2.3. Tablets
  • 11.3. Topical
  • 11.4. Transdermal

12. Sexual & Reproductive Health Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy
    • 12.3.1. Chain Pharmacy
    • 12.3.2. Independent Pharmacy

13. Sexual & Reproductive Health Drugs Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals
    • 13.3.1. Private Hospitals
    • 13.3.2. Public Hospitals

14. Sexual & Reproductive Health Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Sexual & Reproductive Health Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Sexual & Reproductive Health Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Bayer AG
    • 17.3.2. Pfizer Inc.
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. AbbVie Inc.
    • 17.3.5. Ferring B.V.
    • 17.3.6. Teva Pharmaceutical Industries Limited
    • 17.3.7. Organon & Co.
    • 17.3.8. Gedeon Richter Plc
    • 17.3.9. HRA Pharma SAS
    • 17.3.10. Eli Lilly and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INTRAUTERINE SYSTEM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY FERTILITY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GNRH ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY GONADOTROPINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVULATION INDUCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HIV PREVENTION ANTIRETROVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TENOFOVIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TENOFOVIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ESTROGEN THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ESTROGEN THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ESTROGEN THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ESTROGEN THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PROGESTERONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PROGESTERONE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PROGESTERONE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PROGESTERONE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PROGESTERONE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PROGESTERONE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HORMONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY NON HORMONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY POWDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL SEXUAL & REPRODUCTIVE HEALTH DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)

TABLE 27